Weekly ixabepilone with or without biweekly bevacizumab in the treatment of recurrent or persistent uterine and ovarian/primary peritoneal/fallopian tube cancers: A retrospective review
- 1 June 2015
- journal article
- research article
- Published by Elsevier in Gynecologic Oncology
- Vol. 137 (3) , 392-400
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- A randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancerBreast Cancer Research and Treatment, 2013
- OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube CancerJournal of Clinical Oncology, 2012
- Phase II Trial of Bevacizumab in Recurrent or Persistent Endometrial Cancer: A Gynecologic Oncology Group StudyJournal of Clinical Oncology, 2011
- Phase II Clinical Trial of Ixabepilone in Patients With Recurrent or Persistent Platinum- and Taxane-Resistant Ovarian or Primary Peritoneal Cancer: A Gynecologic Oncology Group StudyJournal of Clinical Oncology, 2010
- Phase II Trial of Ixabepilone As Second-Line Treatment in Advanced Endometrial Cancer: Gynecologic Oncology Group Trial 129-PJournal of Clinical Oncology, 2009
- Is There a Taxane-Free Interval That Predicts Response to Taxanes as a Later-Line Treatment of Recurrent Ovarian or Primary Peritoneal Cancer?International Journal of Gynecological Cancer, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast CancerNew England Journal of Medicine, 2007
- The anti-angiogenic basis of metronomic chemotherapyNature Reviews Cancer, 2004
- Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741Journal of Clinical Oncology, 2003